Eton Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Eton Pharmaceuticals has been growing earnings at an average annual rate of 50.9%, while the Pharmaceuticals industry saw earnings declining at 0.4% annually. Revenues have been growing at an average rate of 54.7% per year. Eton Pharmaceuticals's return on equity is 5.9%, and it has net margins of 2.7%.
Key information
50.9%
Earnings growth rate
64.0%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 54.7% |
Return on equity | 5.9% |
Net Margin | 2.7% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%
Jan 09The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot
Dec 13Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point
Nov 16Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money
Sep 30Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%
Jul 25Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Jun 29Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?
Dec 22Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous
Sep 13Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story
Aug 14Eton Pharma jumps 20% on FDA approval of seizure therapy
Jul 18Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher
Apr 15Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely
Oct 14Another Look At Eton Pharmaceuticals
Sep 03What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates
Aug 18Eton Pharma wins FDA approval for Rezipres
Jun 15FDA declines to approve Eton Pharmaceuticals' methanol poisoning treatment
May 28Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner
May 15Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Apr 05Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?
Mar 01Eton Pharma buys Canadian rights for Alkindi Sprinkle
Jan 14Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit
Jan 07FDA accepts Eton application for Topiramate for partial seizures
Dec 17Eton Pharmaceuticals announces availability of ALKINDI SPRINKLE in U.S.
Nov 24Revenue & Expenses Breakdown
How Eton Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 34 | 1 | 19 | 3 |
31 Dec 23 | 32 | -1 | 19 | 3 |
30 Sep 23 | 33 | 2 | 19 | 3 |
30 Jun 23 | 29 | 0 | 19 | 3 |
31 Mar 23 | 24 | -6 | 19 | 3 |
31 Dec 22 | 21 | -9 | 19 | 4 |
30 Sep 22 | 19 | -9 | 18 | 4 |
30 Jun 22 | 16 | -12 | 17 | 6 |
31 Mar 22 | 12 | -12 | 15 | 7 |
31 Dec 21 | 22 | -2 | 14 | 6 |
30 Sep 21 | 16 | -11 | 14 | 9 |
30 Jun 21 | 15 | -11 | 15 | 9 |
31 Mar 21 | 12 | -14 | 14 | 9 |
31 Dec 20 | 0 | -28 | 13 | 14 |
30 Sep 20 | 0 | -23 | 11 | 11 |
30 Jun 20 | 1 | -21 | 10 | 11 |
31 Mar 20 | 1 | -20 | 9 | 11 |
31 Dec 19 | 1 | -18 | 8 | 12 |
30 Sep 19 | 1 | -42 | 6 | 12 |
30 Jun 19 | 1 | -40 | 6 | 11 |
31 Mar 19 | 1 | -41 | 5 | 11 |
31 Dec 18 | 0 | -37 | 5 | 6 |
30 Sep 18 | 0 | -18 | 6 | 7 |
Quality Earnings: ETON has high quality earnings.
Growing Profit Margin: ETON became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ETON has become profitable over the past 5 years, growing earnings by 50.9% per year.
Accelerating Growth: ETON has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ETON has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.9%).
Return on Equity
High ROE: ETON's Return on Equity (5.9%) is considered low.